|
|
Gene Symbol |
ESR1 |
|
Aliases |
ER, ESR, ESRA, ESTRR, Era, NR3A1 |
|
Entrez Gene ID |
|
|
Gene Name |
Estrogen receptor 1 |
|
Chromosomal Location |
6q25.1-q25.2 |
|
HGNC ID |
|
|
Summary |
This gene encodes an estrogen receptor, a ligand-activated transcription factor composed of several domains important for hormone binding, DNA binding, and activation of transcription. The protein localizes to the nucleus where it may form a homodimer or a heterodimer with estrogen receptor 2. Estrogen and its receptors are essential for sexual development and reproductive function, but also play a role in other tissues such as bone. Estrogen receptors are also involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. Alternative promoter usage and alternative splicing result in dozens of transcript variants, but the full-length nature of many of these variants has not been determined. [provided by RefSeq, Mar 2014]
|
|
RefSeq DNA |
|
|
RefSeq mRNA |
|
|
e!Ensembl
Gene |
|
|
Transcript |
ENST00000404742, ENST00000338799, ENST00000446550, ENST00000206249, ENST00000406599, ENST00000427531, ENST00000415488, ENST00000440973, ENST00000443427, ENST00000638569, ENST00000456483 |
|
Protein |
ENSP00000385373, ENSP00000342630, ENSP00000411105, ENSP00000206249, ENSP00000384064, ENSP00000394721, ENSP00000401995, ENSP00000405330, ENSP00000387500, ENSP00000491412, ENSP00000415934
|
|
|
Gene Ontology (GO)
GO ID |
Ontology |
Function |
Evidence |
Reference |
GO:0000122 |
Biological process |
Negative regulation of transcription by RNA polymerase II |
IMP |
20388878 |
GO:0006338 |
Biological process |
Chromatin remodeling |
NAS |
12351687 |
GO:0006351 |
Biological process |
Transcription, DNA-templated |
TAS |
2040605 |
GO:0006355 |
Biological process |
Regulation of transcription, DNA-templated |
NAS |
3753802 |
GO:0006366 |
Biological process |
Transcription by RNA polymerase II |
IDA |
15831516 |
GO:0007165 |
Biological process |
Signal transduction |
TAS |
10749889, 10970861 |
GO:0010629 |
Biological process |
Negative regulation of gene expression |
IDA |
21695196 |
GO:0030520 |
Biological process |
Intracellular estrogen receptor signaling pathway |
IDA |
9841876 |
GO:0030520 |
Biological process |
Intracellular estrogen receptor signaling pathway |
NAS |
3753802 |
GO:0032355 |
Biological process |
Response to estradiol |
IDA |
15304487 |
GO:0043124 |
Biological process |
Negative regulation of I-kappaB kinase/NF-kappaB signaling |
IDA |
7651415, 16043358 |
GO:0043433 |
Biological process |
Negative regulation of DNA-binding transcription factor activity |
IDA |
10816575 |
GO:0043627 |
Biological process |
Response to estrogen |
IDA |
11581164 |
GO:0045893 |
Biological process |
Positive regulation of transcription, DNA-templated |
IDA |
9841876, 20074560 |
GO:0045899 |
Biological process |
Positive regulation of RNA polymerase II transcriptional preinitiation complex assembly |
IDA |
9841876 |
GO:0045944 |
Biological process |
Positive regulation of transcription by RNA polymerase II |
IDA |
11544182, 12047722, 15345745, 15831516, 18563714 |
GO:0051091 |
Biological process |
Positive regulation of DNA-binding transcription factor activity |
IDA |
9328340, 10681512 |
GO:0071168 |
Biological process |
Protein localization to chromatin |
IMP |
20388878 |
GO:0071392 |
Biological process |
Cellular response to estradiol stimulus |
IDA |
15831516 |
GO:1903799 |
Biological process |
Negative regulation of production of miRNAs involved in gene silencing by miRNA |
IMP |
20388878 |
GO:0000790 |
Cellular component |
Nuclear chromatin |
IDA |
15831516, 20388878 |
GO:0005634 |
Cellular component |
Nucleus |
IDA |
9841876, 15569929, 17505058, 20074560, 20080953 |
GO:0005737 |
Cellular component |
Cytoplasm |
IDA |
17505058 |
GO:0005886 |
Cellular component |
Plasma membrane |
IDA |
15569929 |
GO:0016020 |
Cellular component |
Membrane |
NAS |
11960618 |
GO:0032991 |
Cellular component |
Protein-containing complex |
IMP |
11595744 |
GO:0035327 |
Cellular component |
Transcriptionally active chromatin |
IDA |
17505058 |
GO:0097550 |
Cellular component |
Transcriptional preinitiation complex |
IDA |
9841876 |
GO:0000978 |
Molecular function |
RNA polymerase II proximal promoter sequence-specific DNA binding |
IDA |
12047722, 15345745 |
GO:0000981 |
Molecular function |
DNA-binding transcription factor activity, RNA polymerase II-specific |
ISM |
19274049 |
GO:0000981 |
Molecular function |
DNA-binding transcription factor activity, RNA polymerase II-specific |
NAS |
19274049 |
GO:0001093 |
Molecular function |
TFIIB-class transcription factor binding |
IPI |
9841876 |
GO:0001223 |
Molecular function |
Transcription coactivator binding |
IPI |
21642474 |
GO:0001228 |
Molecular function |
DNA-binding transcription activator activity, RNA polymerase II-specific |
IDA |
12047722 |
GO:0003682 |
Molecular function |
Chromatin binding |
IDA |
17505058 |
GO:0003700 |
Molecular function |
DNA-binding transcription factor activity |
NAS |
12552091 |
GO:0004879 |
Molecular function |
Nuclear receptor activity |
IDA |
15831516 |
GO:0004879 |
Molecular function |
Nuclear receptor activity |
IGI |
18722177 |
GO:0005515 |
Molecular function |
Protein binding |
IPI |
1517211, 7641693, 7651415, 9328340, 9627117, 9628876, 9653119, 10359819, 10816575, 10866662, 11032808, 11178989, 11265755, 11279242, 11353774, 11477071, 11581164, 11682626, 11875103, 12039952, 12093804, 12612073, 12660241, 12904255, 12917342, 14701856, 14764652, 14963108, 15199063, 1 |
GO:0008013 |
Molecular function |
Beta-catenin binding |
IPI |
15304487 |
GO:0008134 |
Molecular function |
Transcription factor binding |
IPI |
17505058 |
GO:0017025 |
Molecular function |
TBP-class protein binding |
IPI |
11595744 |
GO:0019899 |
Molecular function |
Enzyme binding |
IPI |
12039952, 22853951 |
GO:0019901 |
Molecular function |
Protein kinase binding |
IPI |
28068668 |
GO:0030235 |
Molecular function |
Nitric-oxide synthase regulator activity |
NAS |
12389206 |
GO:0030284 |
Molecular function |
Estrogen receptor activity |
IDA |
9841876, 15831516 |
GO:0030284 |
Molecular function |
Estrogen receptor activity |
NAS |
3753802 |
GO:0030284 |
Molecular function |
Estrogen receptor activity |
TAS |
11004670 |
GO:0030331 |
Molecular function |
Estrogen receptor binding |
IPI |
9841876 |
GO:0034056 |
Molecular function |
Estrogen response element binding |
IDA |
9841876, 15345745, 15831516, 17975005 |
GO:0042802 |
Molecular function |
Identical protein binding |
IPI |
11265755, 11682626, 21182205, 23065768 |
GO:0051117 |
Molecular function |
ATPase binding |
IDA |
12058073 |
|
Protein Information |
|
Protein Name |
Estrogen receptor, E2 receptor alpha, ER-alpha, estradiol receptor, estrogen nuclear receptor alpha, estrogen receptor alpha E1-E2-1-2, estrogen receptor alpha E1-N2-E2-1-2, nuclear receptor subfamily 3 group A member 1, oestrogen receptor alpha |
|
Function |
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full-length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1. |
|
|
|
|
|
UniProt |
|
|
PDB |
5N10, 4JC3, 4JDD, 6HHP, 6HKB, 6HKF, 6HMU, 1A52, 1AKF, 1ERE, 1ERR, 1G50, 1GWQ, 1GWR, 1HCP, 1HCQ, 1L2I, 1PCG, 1QKT, 1QKU, 1R5K, 1SJ0, 1UOM, 1X7E, 1X7R, 1XP1, 1XP6, 1XP9, 1XPC, 1XQC, 1YIM, 1YIN, 1ZKY, 2AYR, 2B1V, 2B1Z, 2B23, 2BJ4, 2FAI, 2G44, 2G5O, 2I0J, 2IOG, 2IOK, 2JF9, 2JFA, 2LLO, 2LLQ, 2OCF, 2OUZ, 2P15, |
|
|
|
Interactions |
| |
STRING |
MINT |
IntAct |
ENSP00000373487 |
P05783 |
P05783 |
|
| |
View interactions
|
|
| |
Associated Diseases
Disease group | Disease Name | References |
Cardiovascular Diseases |
Myocardial Infarction |
|
Atherosclerosis |
|
Arteriosclerosis |
|
Ear Or Mastoid Diseases |
Meniere Disease |
|
Endocrine System Diseases |
Estrogen Resistance |
|
PCOS |
|
Musculoskeletal Diseases |
Bone Diseases |
|
Neoplasms |
Liver Cancer |
|
Breast Cancer |
17553133, 16280033, 10945602, 23236557, 17545528, 20104649, 21541733, 20966540, 24185510, 21501481, 22038807, 27580430, 23001124, 24014025, 17417639, 20458558, 22174584, 24185512, 25330770, 29059683, 22976474, 24398047, 17224074 |
Mesothelioma |
|
Lung Cancer |
|
Intracranial Astrocytoma |
|
Prostate cancer |
|
Uterine Fibroids |
|
Grade I Astrocytoma |
|
Childhood Cerebral Astrocytoma |
|
Adenocarcinoma |
|
Fibroid Tumor |
|
Astrocytoma |
|
Neuroblastoma |
|
Endometrial Cancer |
|
Cerebral Astrocytoma |
|
Bladder Cancer |
|
Carcinoma |
|
Leukemia |
|
Anaplastic Carcinoma |
|
Oligoastrocytoma |
|
Prostatic Intraepithelial Neoplasias |
|
Cribriform Carcinoma |
|
Vulvar Cancer |
|
Nervous System Diseases |
Migraine |
|
Sick Headaches |
|
Nutritional and Metabolic Diseases |
Osteopenia |
|
Obesity |
|
Metabolic Bone Disorder |
|
Psychiatric/Brain disorders |
Mood Disorders |
|
Schizophrenia |
|
Mental Depression |
|
Bipolar Disorder |
|
Shared Paranoid Disorder |
|
Alzheimer Disease |
|
Senile Dementia |
|
Renal Disorder |
Nephritis |
|
Glomerulonephritis |
|
Reproductive disorders |
Oligospermia |
|
Male infertility |
|
Subfertility, Female |
|
Endometriosis |
|
Female Urogenital Diseases |
|
Preeclampsia |
|
|
References |
|
|
|
PubMed ID |
Associated gene/s |
Associated condition |
Genetic Mutation |
Diagnostic Criteria |
Association with PCOS |
Ethnicity |
Conclusion |
|
PR |
Infertility |
|
|
Related
|
|
The endometrial histopathological changes and local decrease or absence of ER and PR in PCOS might be one of the causal factors of infertility. |
|
ERbeta |
Abnormal follicular development |
|
NIH |
Related
|
|
The results of this study demonstrate that there are significant alterations in the expression of ERalpha and ERbeta in PCOS that may be related to abnormal follicular development. |
|
Er and PR |
Spontaneous abortion |
|
|
Related
|
|
The decrease of ER and PR of endometrial in the PCOS patients, may be a reason for spontaneous abortion, and the cyclical irregularity of ER and PR in the PCOS patients is another cause of spontaneous abortion. |
|
Androgen receptor (AR), estrogen receptor beta (ERbeta), co-activators AIB1 and ARA70 |
Endometrial hyperplasia |
|
|
Related
|
|
The PCOS endometrium exhibits a higher sensitivity to steroid action. We can inferred that these alterations could deregulate the transcription of genes involved in the cell cycle, which may lead to the development of endometrial hyperplasia in PCOS women. |
|
ER and the novel G protein-coupled ER (GPR30) |
Infertility |
|
|
Related
|
Chinese- 15 PCOS and 15 controls |
The study proposes that restored receptor expression might improve endometrial receptivity and help lower infertility associated with PCOS. |
|
|
|
|